drugset / Trial / NCT02743637
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
Timeline
- Start
- 2016-02
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evexomostat | Other / unclassified | — | Subcutaneous |